1
|
Haider MT, Freytag V, Krause L, Spethmann T, Gosau T, Beine MC, Knies C, Schröder-Schwarz J, Horn M, Riecken K, Lange T. Comparison of ex vivo bioluminescence imaging, Alu-qPCR and histology for the quantification of spontaneous lung and bone metastases in subcutaneous xenograft mouse models. Clin Exp Metastasis 2024; 41:103-115. [PMID: 38353934 PMCID: PMC10972982 DOI: 10.1007/s10585-024-10268-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Accepted: 01/16/2024] [Indexed: 03/28/2024]
Abstract
Bioluminescence imaging (BLI) is a non-invasive state-of-the-art-method for longitudinal tracking of tumor cells in mice. The technique is commonly used to determine bone metastatic burden in vivo and also suitable ex vivo to detect even smallest bone micro-metastases in spontaneous metastasis xenograft models. However, it is unclear to which extent ex vivo BLI correlates with alternative methods for metastasis quantification. Here, we compared ex vivo BLI, human DNA-based Alu-qPCR, and histology for the quantification of bone vs. lung metastases, which are amongst the most common sites of metastasis in prostate cancer (PCa) patients and spontaneous PCa xenograft models. Data from 93 immunodeficient mice were considered, each of which were subcutaneously injected with luciferase/RGB-labeled human PCa PC-3 cells. The primary tumors were resected at ~ 0.75 cm³ and mice were sacrificed ~ 3 weeks after surgery and immediately examined by ex vivo BLI. Afterwards, the right lungs and hind limbs with the higher BLI signal (BLIHi bone) were processed for histology, whereas the left lung lobes and hind limbs with the lower BLI signal (BLILo bone) were prepared for Alu-qPCR. Our data demonstrate remarkable differences in the correlation coefficients of the different methods for lung metastasis detection (r ~ 0.8) vs. bone metastasis detection (r ~ 0.4). However, the BLI values of the BLIHi and BLILo bones correlated very strongly (r ~ 0.9), indicating that the method per se was reliable under identical limitations; the overall level of metastasis to contralateral bones was astonishingly similar. Instead, the level of lung metastasis only weakly to moderately correlated with the level of bone metastasis formation. Summarized, we observed a considerable discrepancy between ex vivo BLI and histology/Alu-qPCR in the quantification of bone metastases, which was not observed in the case of lung metastases. Future studies using ex vivo BLI for bone metastasis quantification should combine multiple methods to accurately determine metastatic load in bone samples.
Collapse
Affiliation(s)
- Marie-Therese Haider
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Vera Freytag
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Linda Krause
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tanja Spethmann
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Tobias Gosau
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Mia C Beine
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Christine Knies
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Jennifer Schröder-Schwarz
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany
| | - Michael Horn
- Core Facility In Vivo Optical Imaging, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Mildred Scheel Cancer Career Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Kristoffer Riecken
- Research Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tobias Lange
- Institute of Anatomy and Experimental Morphology, University Medical Center Hamburg- Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany.
- Institute of Anatomy I, University Hospital Jena, Teichgraben 7, Jena, 07743, Germany.
- Comprehensive Cancer Center Central Germany (CCCG), Ulm, Germany.
| |
Collapse
|
2
|
Li J, Wu J, Xie Y, Yu X. Bone marrow adipocytes and lung cancer bone metastasis: unraveling the role of adipokines in the tumor microenvironment. Front Oncol 2024; 14:1360471. [PMID: 38571500 PMCID: PMC10987778 DOI: 10.3389/fonc.2024.1360471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2023] [Accepted: 03/08/2024] [Indexed: 04/05/2024] Open
Abstract
Bone is a common site of metastasis for lung cancer. The "seed and soil" hypothesis suggests that the bone marrow microenvironment ("soil") may provide a conducive survival environment for metastasizing tumor cells ("seeds"). The bone marrow microenvironment, comprising a complex array of cells, includes bone marrow adipocytes (BMAs), which constitute about 70% of the adult bone marrow volume and may play a significant role in tumor bone metastasis. BMAs can directly provide energy for tumor cells, promoting their proliferation and migration. Furthermore, BMAs participate in the tumor microenvironment's osteogenesis regulation, osteoclast(OC) regulation, and immune response through the secretion of adipokines, cytokines, and inflammatory factors. However, the precise mechanisms of BMAs in lung cancer bone metastasis remain largely unclear. This review primarily explores the role of BMAs and their secreted adipokines (leptin, adiponectin, Nesfatin-1, Resistin, chemerin, visfatin) in lung cancer bone metastasis, aiming to provide new insights into the mechanisms and clinical treatment of lung cancer bone metastasis.
Collapse
Affiliation(s)
- Jian Li
- Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China
- Department of Endocrinology and Metabolism, Shandong Second Provincial General Hospital, Jinan, China
| | - Jialu Wu
- Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China
| | - Yanni Xie
- Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China
| | - Xijie Yu
- Laboratory of Endocrinology and Metabolism/Department of Endocrinology and Metabolism, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
3
|
Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials. Front Oncol 2023; 13:1133828. [PMID: 36860316 PMCID: PMC9969102 DOI: 10.3389/fonc.2023.1133828] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Accepted: 02/01/2023] [Indexed: 02/16/2023] Open
Abstract
Denosumab, a fully humanized monoclonal neutralizing antibody, inhibits activation of the RANK/RANKL/OPG signaling pathway through competitive binding with RANKL, thereby inhibiting osteoclast-mediated bone resorption. Denosumab inhibits bone loss; therefore, it is used to treat metabolic bone diseases (including postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis), in clinical practice. Since then, multiple effects of denosumab have been discovered. A growing body of evidence suggests that denosumab has a variety of pharmacological activities and broad potential in clinical diseases such as osteoarthritis, bone tumors, and other autoimmune diseases. Currently, Denosumab is emerging as a treatment for patients with malignancy bone metastases, and it also shows direct or indirect anti-tumor effects in preclinical models and clinical applications. However, as an innovative drug, its clinical use for bone metastasis of malignant tumors is still insufficient, and its mechanism of action needs to be further investigated. This review systematically summarizes the pharmacological mechanism of action of denosumab and the current understanding and clinical practice of the use of denosumab for bone metastasis of malignant tumors to help clinicians and researchers deepen their understanding of denosumab.
Collapse
Affiliation(s)
- Junjie Lu
- Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Desheng Hu
- Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Yan Zhang
- Department of Pain, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Chen Ma
- Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Lin Shen
- Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Bo Shuai
- Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,*Correspondence: Bo Shuai,
| |
Collapse
|
4
|
Osteolytic vs. Osteoblastic Metastatic Lesion: Computational Modeling of the Mechanical Behavior in the Human Vertebra after Screws Fixation Procedure. J Clin Med 2022; 11:jcm11102850. [PMID: 35628977 PMCID: PMC9144065 DOI: 10.3390/jcm11102850] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 05/11/2022] [Accepted: 05/16/2022] [Indexed: 12/27/2022] Open
Abstract
Metastatic lesions compromise the mechanical integrity of vertebrae, increasing the fracture risk. Screw fixation is usually performed to guarantee spinal stability and prevent dramatic fracture events. Accordingly, predicting the overall mechanical response in such conditions is critical to planning and optimizing surgical treatment. This work proposes an image-based finite element computational approach describing the mechanical behavior of a patient-specific instrumented metastatic vertebra by assessing the effect of lesion size, location, type, and shape on the fracture load and fracture patterns under physiological loading conditions. A specific constitutive model for metastasis is integrated to account for the effect of the diseased tissue on the bone material properties. Computational results demonstrate that size, location, and type of metastasis significantly affect the overall vertebral mechanical response and suggest a better way to account for these parameters in estimating the fracture risk. Combining multiple osteolytic lesions to account for the irregular shape of the overall metastatic tissue does not significantly affect the vertebra fracture load. In addition, the combination of loading mode and metastasis type is shown for the first time as a critical modeling parameter in determining fracture risk. The proposed computational approach moves toward defining a clinically integrated tool to improve the management of metastatic vertebrae and quantitatively evaluate fracture risk.
Collapse
|
5
|
An ancient cranium from Dmanisi: Evidence for interpersonal violence, disease, and possible predation by carnivores on Early Pleistocene Homo. J Hum Evol 2022; 166:103180. [DOI: 10.1016/j.jhevol.2022.103180] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2021] [Revised: 02/22/2022] [Accepted: 02/22/2022] [Indexed: 12/11/2022]
|
6
|
Bădilă AE, Rădulescu DM, Niculescu AG, Grumezescu AM, Rădulescu M, Rădulescu AR. Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review. Cancers (Basel) 2021; 13:4229. [PMID: 34439383 PMCID: PMC8392383 DOI: 10.3390/cancers13164229] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/14/2021] [Accepted: 08/20/2021] [Indexed: 12/13/2022] Open
Abstract
In the last decades, the treatment of primary and secondary bone tumors has faced a slow-down in its development, being mainly based on chemotherapy, radiotherapy, and surgical interventions. However, these conventional therapeutic strategies present a series of disadvantages (e.g., multidrug resistance, tumor recurrence, severe side effects, formation of large bone defects), which limit their application and efficacy. In recent years, these procedures were combined with several adjuvant therapies, with different degrees of success. To overcome the drawbacks of current therapies and improve treatment outcomes, other strategies started being investigated, like carrier-mediated drug delivery, bone substitutes for repairing bone defects, and multifunctional scaffolds with bone tissue regeneration and antitumor properties. Thus, this paper aims to present the types of bone tumors and their current treatment approaches, further focusing on the recent advances in new therapeutic alternatives.
Collapse
Affiliation(s)
- Adrian Emilian Bădilă
- “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (A.E.B.); (D.M.R.); (A.R.R.)
- Department of Orthopedics and Traumatology, Bucharest University Hospital, 050098 Bucharest, Romania
| | - Dragoș Mihai Rădulescu
- “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (A.E.B.); (D.M.R.); (A.R.R.)
- Department of Orthopedics and Traumatology, Bucharest University Hospital, 050098 Bucharest, Romania
| | - Adelina-Gabriela Niculescu
- Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 060042 Bucharest, Romania; (A.-G.N.); (A.M.G.)
| | - Alexandru Mihai Grumezescu
- Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, 060042 Bucharest, Romania; (A.-G.N.); (A.M.G.)
- Research Institute of the University of Bucharest—ICUB, University of Bucharest, 050657 Bucharest, Romania
- Academy of Romanian Scientists, 3 Ilfov Street, 50044 Bucharest, Romania
| | - Marius Rădulescu
- Department of Inorganic Chemistry, Physical Chemistry and Electrochemistry, University Politehnica of Bucharest, 1-7 Polizu St., 011061 Bucharest, Romania
| | - Adrian Radu Rădulescu
- “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; (A.E.B.); (D.M.R.); (A.R.R.)
- Department of Orthopedics and Traumatology, Bucharest University Hospital, 050098 Bucharest, Romania
| |
Collapse
|
7
|
Jerez S, Pliego E, Solis FJ. Strange attractors in discrete slow power-law models of bone remodeling. CHAOS (WOODBURY, N.Y.) 2021; 31:033109. [PMID: 33810734 DOI: 10.1063/5.0038760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 02/16/2021] [Indexed: 06/12/2023]
Abstract
Recently, a family of nonlinear mathematical discrete systems to describe biological interactions was considered. Such interactions are modeled by power-law functions where the exponents involve regulation processes. Considering exponent values giving rise to hyperbolic equilibria, we show that the systems exhibit irregular behavior characterized by strange attractors. The systems are numerically analyzed for different parameter values. Depending on the initial conditions, the orbits of each system either diverge to infinity or approach a periodic orbit or a strange attractor. Such dynamical behavior is identified by their Lyapunov exponents and local dimension. Finally, an application to the biochemical process of bone remodeling is presented. The existence of deterministic chaos in this process reveals a possible explanation of reproducibility failure and variation of effects in clinical experiments.
Collapse
|
8
|
Phelps TE, Roy J, Green MV, Seidel J, Baidoo KE, Adler S, Edmondson EF, Butcher D, Matta JL, Ton AT, Wong K, Huang S, Ren L, LeBlanc AK, Choyke PL, Jagoda EM. Sodium Fluoride-18 and Radium-223 Dichloride Uptake Colocalize in Osteoblastic Mouse Xenograft Tumors. Cancer Biother Radiopharm 2021; 36:133-142. [PMID: 33646017 DOI: 10.1089/cbr.2020.4068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background: Patients with osteoblastic bone metastases are candidates for radium-223 (223RaCl2) therapy and may undergo sodium fluoride-18 (18F-NaF) positron emission tomography-computed tomography imaging to identify bone lesions. 18F-NaF has been shown to predict 223RaCl2 uptake, but intratumor distributions of these two agents remain unclear. In this study, the authors evaluate the spatial distribution and relative uptakes of 18F-NaF and 223RaCl2 in Hu09-H3 human osteosarcoma mouse xenograft tumors at macroscopic and microscopic levels to better quantify their correlation. Materials and Methods: 18F-NaF and 223RaCl2 were co-injected into Hu09-H3 xenograft tumor severe combined immunodeficient mice. Tumor content was determined from in vivo biodistributions and visualized by PET, single photon emission computed tomography, and CT imaging. Intratumor distributions were visualized by quantitative autoradiography of tumor tissue sections and compared to histology of the same or adjacent sections. Results: 18F and 223Ra accumulated in proportional amounts in whole Hu09-H3 tumors (r2 = 0.82) and in microcalcified regions within these tumors (r2 = 0.87). Intratumor distributions of 18F and 223Ra were spatially congruent in these microcalcified regions. Conclusions: 18F-NaF and 223RaCl2 uptake are strongly correlated in heterogeneously distributed microcalcified regions of Hu09-H3 xenograft tumors, and thus, tumor accumulation of 18F is predictive of 223Ra accumulation. Hu09-H3 xenograft tumors appear to possess certain histopathological features found in patients with metastatic bone disease and may be useful in clarifying the relationship between administered 223Ra dose and therapeutic effect.
Collapse
Affiliation(s)
- Tim E Phelps
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Jyoti Roy
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Michael V Green
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.,Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland, USA
| | - Jurgen Seidel
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.,Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland, USA
| | - Kwamena E Baidoo
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Stephen Adler
- Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland, USA
| | - Elijah F Edmondson
- Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, NCI, Frederick, Maryland, USA
| | - Donna Butcher
- Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, NCI, Frederick, Maryland, USA
| | - Jennifer L Matta
- Molecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, NCI, Frederick, Maryland, USA
| | - Anita T Ton
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Karen Wong
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Shan Huang
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Ling Ren
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Amy K LeBlanc
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Peter L Choyke
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Elaine M Jagoda
- Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
9
|
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2. Int J Mol Sci 2020; 21:ijms21186723. [PMID: 32937821 PMCID: PMC7555756 DOI: 10.3390/ijms21186723] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 09/07/2020] [Accepted: 09/12/2020] [Indexed: 12/14/2022] Open
Abstract
Osteolytic bone lesions are one of the central features of multiple myeloma (MM) and lead to bone pain, fractures, decreased quality of life, and decreased survival. Dysfunction of the osteoclast (OC)/osteoblast (OB) axis plays a key role in the development of myeloma-associated osteolytic lesions. Many signaling pathways and factors are associated with myeloma bone diseases (MBDs), including the RANKL/OPG and NF-κB pathways. NRF2, a master regulator of inflammatory signaling, might play a role in the regulation of bone metabolism via anti-inflammatory signaling and decreased reactive oxygen species (ROS) levels. The loss of NRF2 expression in OCs reduced bone mass via the RANK/RANKL pathway and other downstream signaling pathways that affect osteoclastogenesis. The NRF2 level in OBs could interfere with interleukin (IL)-6 expression, which is associated with bone metabolism and myeloma cells. In addition to direct impact on OCs and OBs, the activity of NRF2 on myeloma cells and mesenchymal stromal cells influences the inflammatory stress/ROS level in these cells, which has an impact on OCs, OBs, and osteocytes. The interaction between these cells and OCs affects the osteoclastogenesis of myeloma bone lesions associated with NRF2. Therefore, we have reviewed the effects of NRF2 on OCs and OBs in MBDs.
Collapse
|
10
|
Bouvard B, Pascaretti-Grizon F, Legrand E, Lavigne C, Audran M, Chappard D. Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms. Morphologie 2020; 104:97-108. [PMID: 32127247 DOI: 10.1016/j.morpho.2020.01.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Revised: 01/22/2020] [Accepted: 01/22/2020] [Indexed: 01/06/2023]
Abstract
Osteoporosis is considered the most frequent skeletal manifestation of systemic mastocytosis (SM). We performed a retrospective analysis of sixty patients (37 males and 23 females) who underwent a bone biopsy in the assessment of SM or in the assessment of unexplained bone fragility. Thirty-three had simultaneously a bone marrow biopsy with a Jamshidi's needle; this sample was used for immunohistochemical analysis (tryptase, c-KIT. CD20, VCAM-1). Bone biopsy was realized in 42 cases in the assessment of SM to provide histologic proof of the disease and in 18 cases in the assessment of unexplained bone fragility and surprisingly revealed a SM. An increased bone turnover was observed in patients with SM with elevated eroded surfaces, osteoclast number and bone formation rate. In addition to nodules of mast cells (MC), a high number of MC was directly apposed on the trabeculae, affixed on the osteoblasts or the lining cells. The VCAM-1 adhesion protein recognizing α4β7 and α4β1 integrins may be a candidate to explain this particular adherence. One third of the bone marrow biopsies did not exhibit MC nodules or MC infiltration and led to a false negative diagnosis for SM. SM can be discovered in the assessment of fracture or osteoporosis. Transiliac bone biopsy allows for the diagnosis of the disease more accurately than bone marrow biopsy; it also provides a histomorphometric analysis of bone remodeling.
Collapse
Affiliation(s)
- B Bouvard
- Groupe études remodelage osseux et biomatériaux (GEROM), EA-4658, SFR-4208, IRIS-Institut de Biologie en Santé (IBS), université d'Angers, CHU d'Angers, 49933 Angers, France; Department of rheumatology, CHU d'Angers, 49933 Angers cedex, France
| | - F Pascaretti-Grizon
- Groupe études remodelage osseux et biomatériaux (GEROM), EA-4658, SFR-4208, IRIS-Institut de Biologie en Santé (IBS), université d'Angers, CHU d'Angers, 49933 Angers, France
| | - E Legrand
- Groupe études remodelage osseux et biomatériaux (GEROM), EA-4658, SFR-4208, IRIS-Institut de Biologie en Santé (IBS), université d'Angers, CHU d'Angers, 49933 Angers, France; Department of rheumatology, CHU d'Angers, 49933 Angers cedex, France
| | - C Lavigne
- Department of internal medicine, CHU d'Angers, 49933 Angers cedex, France
| | - M Audran
- Groupe études remodelage osseux et biomatériaux (GEROM), EA-4658, SFR-4208, IRIS-Institut de Biologie en Santé (IBS), université d'Angers, CHU d'Angers, 49933 Angers, France; Department of rheumatology, CHU d'Angers, 49933 Angers cedex, France
| | - D Chappard
- Groupe études remodelage osseux et biomatériaux (GEROM), EA-4658, SFR-4208, IRIS-Institut de Biologie en Santé (IBS), université d'Angers, CHU d'Angers, 49933 Angers, France.
| |
Collapse
|
11
|
Baliyan A, Punia RS, Kundu R, Dhingra H, Aggarwal P, Garg SK. Histopathological Spectrum of Bone Changes in Skeletal Metastasis. Indian J Med Paediatr Oncol 2019. [DOI: 10.4103/ijmpo.ijmpo_142_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Abstract
Background: Metastatic carcinoma is the most common secondary malignant tumor affecting the bone. Bone is the third most common site for metastasis after lung and liver. The present study was planned to analyze the histomorphological patterns of bone changes in metastatic tumors and their correlation with the radiological findings. Materials and Methods: The current prospective study was conducted over a span of 2 years, encompassing 150 patients with clinically and radiologically suspected metastatic bone disease. Bone biopsy samples were studied for the pattern of bone changes. Results: Of 150 total cases, 30 cases had metastatic bone tumors. The age of the patients ranged from 37 to 84 years (mean: 57.57 ± 11.9 years). Male-to-female ratio was 2:1. All patients with metastasis presented with a complaint of pain followed by tenderness (20, 66.7%). The lesions were commonly located in the vertebral column (14, 46.7%), followed by femur (6, 20%). The primary site was known in 21 (70%) cases. The tumor histotypes were adenocarcinoma (23, 76.7%), squamous cell carcinoma (5, 16.7%), pleomorphic sarcoma (1, 3.3%), and malignant melanoma (1, 3.3%). Histomorphological patterns of bone changes were osteolytic (16, 53.3%), mixed (8, 26.7%), and osteoblastic (6, 20.0%). Correlation between the radiological findings and histopathological patterns of metastases was found to be statistically significant. Conclusions: Histomorphological assessment of bone changes in metastasis is an important parameter. Besides the histological categorization of metastatic bone disease, it plays a pivotal role in identification of the primary tumor site.
Collapse
Affiliation(s)
- Asif Baliyan
- Departments of Pathology, Government Medical College and Hospital, Chandigarh, India
| | - Rajpal Singh Punia
- Departments of Pathology, Government Medical College and Hospital, Chandigarh, India
| | - Reetu Kundu
- Departments of Pathology, Government Medical College and Hospital, Chandigarh, India
| | - Harshi Dhingra
- Departments of Pathology, Government Medical College and Hospital, Chandigarh, India
| | - Purnima Aggarwal
- Departments of Radiodiagnosis, Government Medical College and Hospital, Chandigarh, India
| | - Sudhir Kumar Garg
- Departments of Orthopaedics, Government Medical College and Hospital, Chandigarh, India
| |
Collapse
|
12
|
Falcinelli C, Di Martino A, Gizzi A, Vairo G, Denaro V. Mechanical behavior of metastatic femurs through patient-specific computational models accounting for bone-metastasis interaction. J Mech Behav Biomed Mater 2019; 93:9-22. [PMID: 30738327 DOI: 10.1016/j.jmbbm.2019.01.014] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2018] [Revised: 01/23/2019] [Accepted: 01/27/2019] [Indexed: 12/21/2022]
Abstract
This paper proposes a computational model based on a finite-element formulation for describing the mechanical behavior of femurs affected by metastatic lesions. A novel geometric/constitutive description is introduced by modelling healthy bone and metastases via a linearly poroelastic constitutive approach. A Gaussian-shaped graded transition of material properties between healthy and metastatic tissues is prescribed, in order to account for the bone-metastasis interaction. Loading-induced failure processes are simulated by implementing a progressive damage procedure, formulated via a quasi-static displacement-driven incremental approach, and considering both a stress- and a strain-based failure criterion. By addressing a real clinical case, left and right patient-specific femur models are geometrically reconstructed via an ad-hoc imaging procedure and embedding multiple distributions of metastatic lesions along femurs. Significant differences in fracture loads, fracture mechanisms, and damage patterns, are highlighted by comparing the proposed constitutive description with a purely elastic formulation, where the metastasis is treated as a pseudo-healthy tissue or as a void region. Proposed constitutive description allows to capture stress/strain localization mechanisms within the metastatic tissue, revealing the model capability in describing possible strain-induced mechano-biological stimuli driving onset and evolution of the lesion. The proposed approach opens towards the definition of effective computational strategies for supporting clinical decision and treatments regarding metastatic femurs, contributing also to overcome some limitations of actual standards and procedures.
Collapse
Affiliation(s)
- Cristina Falcinelli
- Department of Engineering, Campus Bio-Medico University of Rome, Italy; Department of Civil Engineering & Computer Science, University of Rome "Tor Vergata", Italy
| | - Alberto Di Martino
- Department of Orthopaedics and Trauma Surgery, Campus Bio-Medico University of Rome, Italy; Sideny Kimmel Medical College, Thomas Jefferson University (SKMC), Philadelphia, USA
| | - Alessio Gizzi
- Department of Engineering, Campus Bio-Medico University of Rome, Italy
| | - Giuseppe Vairo
- Department of Civil Engineering & Computer Science, University of Rome "Tor Vergata", Italy.
| | - Vincenzo Denaro
- Department of Orthopaedics and Trauma Surgery, Campus Bio-Medico University of Rome, Italy
| |
Collapse
|
13
|
Ye WL, Zhao YP, Cheng Y, Liu DZ, Cui H, Liu M, Zhang BL, Mei QB, Zhou SY. Bone metastasis target redox-responsive micell for the treatment of lung cancer bone metastasis and anti-bone resorption. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2018; 46:380-391. [PMID: 29336169 DOI: 10.1080/21691401.2018.1426007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In order to inhibit the growth of lung cancer bone metastasis and reduce the bone resorption at bone metastasis sites, a bone metastasis target micelle DOX@DBMs-ALN was prepared. The size and the zeta potential of DOX@DBNs-ALN were about 60 nm and -15 mV, respectively. DOX@DBMs-ALN exhibited high binding affinity with hydroxyapatite and released DOX in redox-responsive manner. DOX@DBMs-ALN was effectively up taken by A549 cells and delivered DOX to the nucleus of A549 cells, which resulted in strong cytotoxicity on A549 cells. The in vivo experimental results indicated that DOX@DBMs-ALN specifically delivered DOX to bone metastasis site and obviously prolonged the retention time of DOX in bone metastasis site. Moreover, DOX@DBMs-ALN not only significantly inhibited the growth of bone metastasis tumour but also obviously reduced the bone resorption at bone metastasis sites without causing marked systemic toxicity. Thus, DOX@DBMs-ALN has great potential in the treatment of lung cancer bone metastasis.
Collapse
Affiliation(s)
- Wei-Liang Ye
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Yi-Pu Zhao
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Ying Cheng
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Dao-Zhou Liu
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Han Cui
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Miao Liu
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Bang-Le Zhang
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China
| | - Qi-Bing Mei
- b Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine , Fourth Military Medical University , Xi'an , China
| | - Si-Yuan Zhou
- a Department of Pharmaceutics, School of Pharmacy , Fourth Military Medical University , Xi'an , China.,b Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine , Fourth Military Medical University , Xi'an , China
| |
Collapse
|
14
|
Kün-Darbois JD, Quenel L, Badja S, Chappard D. Tooth Extraction Locally Stimulates Proliferation of Multiple Myeloma in a Patient with Mandibular Localizations. Acta Haematol 2017; 138:201-207. [PMID: 29207391 DOI: 10.1159/000481425] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 09/11/2017] [Indexed: 01/23/2023]
Abstract
OBJECTIVES Multiple myeloma (MM) is characterized by the occurrence of osteolytic lesions. MM treatment usually involves antiresorptive drugs (mainly bisphosphonates). CASE REPORT A patient with an MM presented osteolytic lesions of the mandible. Extraction of teeth 45 and 46 was performed 5 years after the diagnosis of periodontitis. Four months later, osteonecrosis of the jaw (ONJ) was diagnosed at the extraction site. X-ray showed an extension of osteolytic lesions on the right side, close to the extraction site, without modification of the lesions on the left side. Two months later, a curettage was performed because of a painful bone sequestration. X-ray showed an extension of the osteolytic lesions on the right side. RESULTS Histological analysis found a vascularized plasmacytoma of the soft tissues around the ONJ. Analysis of the bone showed mixed lesions with osteonecrotic areas and living bone resorbed by active osteoclasts surrounding a plasmacytoma. The surface area of the osteolytic foci has considerably increased only close to the extraction site. CONCLUSIONS Tooth extraction triggered an ONJ associated with bisphosphonate treatment. However, it also seemed to induce a considerable proliferation of plasma cells at the extraction site; we hypothesize that it is due to the increase in bone remodeling related to the surgical trauma.
Collapse
|
15
|
Kommalapati A, Tella SH, Esquivel MA, Correa R. Evaluation and management of skeletal disease in cancer care. Crit Rev Oncol Hematol 2017; 120:217-226. [PMID: 29032892 DOI: 10.1016/j.critrevonc.2017.09.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2017] [Revised: 07/15/2017] [Accepted: 09/07/2017] [Indexed: 01/04/2023] Open
Abstract
Recently, there have been considerable advancements in cancer therapies thereby prolonging the life of cancer survivors. However, these recent advancements present new challenges in the management of bone disease in cancer survivors. Bone acts as a fertile soil for cancer seeding and bone health is often compromised because of increased inflammatory cytokines in cancer, direct cancer metastasis and toxic effects of anti-cancer therapies. This effect is more pronounced in elderly population who already have compromised bone mineral density leading to increased skeletal related events and bone pain. Timely diagnosis and effective interventions are essential for reducing bone-related morbidity in cancer survivors. Also, a complex interdependence exists between cancer related bone disease and tumor growth, creating a vicious circle of extensive bone destruction and cancer progression. Hence, maintenance of bone health and integrity plays a pivotal role in comprehensive cancer care. The bone-targeted treatments have been shown to preserve bone health, and modify the course of the underlying cancer. Management of long-term bone health requires a broad knowledge base that endocrinologists, oncologists and other care team members should be aware of. The manuscript highlights the skeletal effects of cancer, adjuvant therapies used for hormone-responsive cancers, chemotherapy induced bone loss and steps for accurate diagnosis and management of bone disease in cancer survivors by bridging the gaps in the comprehensive cancer care.
Collapse
Affiliation(s)
- Anuhya Kommalapati
- Department of Internal Medicine, Washington Hospital Center, Washington DC, USA
| | | | - Mary Angelynne Esquivel
- Endocrinology, Diabetes and Metabolism, Warren Alpert Medical School of Brown University, Rhode Island, USA
| | - Ricardo Correa
- Endocrinology, Diabetes and Metabolism, Warren Alpert Medical School of Brown University, Rhode Island, USA
| |
Collapse
|
16
|
Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2017; 165:129-138. [PMID: 28577080 DOI: 10.1007/s10549-017-4318-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Accepted: 05/24/2017] [Indexed: 01/24/2023]
Abstract
PURPOSE The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the neoadjuvant I-SPY1 study. METHODS We evaluated RANK/RANKL/OPG expression using expression microarrays in I-SPY1 (n = 149). Associations with clinical features were determined using t test and ANOVA. Associations between biomarker high versus low groups (dichotomized at an optimal cutpoint) and recurrence-free survival (RFS) were evaluated using the log-rank test and in a multivariate Cox proportional hazard model. A pooled external neoadjuvant cohort with gene expression data (GSE25066) (Hatzis et al. in JAMA 305(18):1873-1881, 30) (n = 425) was used for validation. Associations with site-specific relapse were evaluated using the t-test and multivariate logistic regression adjusting for hormone receptor (HR) status. RESULTS RANK was significantly higher in HR negative versus HR positive (p = 0.027), in basal versus non-basal disease (p = 0.004), and in those achieving pathologic complete response (p = 0.038); the associations with HR negative and basal BC were also significant in GSE25066. In both datasets, higher RANK associated with significantly worse RFS (I-SPY1: p = 0.045, GSE25066: p = 0.044). However, this association did not remain significant after adjusting for HR status. In I-SPY1 patients with recurrence, higher RANK correlated with BM versus non-BM (p = 0.045), even after adjusting for HR status (p = 0.035). CONCLUSIONS RANK is increased in HR negative and basal BC, and correlates with worse RFS and risk of BM. The RANK pathway is a potential therapeutic target in BC.
Collapse
Affiliation(s)
- Neelima Vidula
- Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
| | - Christina Yau
- University of California, San Francisco, 1600 Divisadero St., San Francisco, CA, 94115, USA
| | - Jiali Li
- Valley Medical Oncology Consultants, Stanford Health Care, 2505 Hospital Drive, Mountain View, CA, 94040, USA
| | - Laura J Esserman
- University of California, San Francisco, 1600 Divisadero St., San Francisco, CA, 94115, USA
| | - Hope S Rugo
- University of California, San Francisco, 1600 Divisadero St., San Francisco, CA, 94115, USA.
| |
Collapse
|
17
|
Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol 2016; 3:240-253. [PMID: 29264192 PMCID: PMC5730836 DOI: 10.1016/j.ajur.2016.08.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Accepted: 08/16/2016] [Indexed: 02/07/2023] Open
Abstract
Recent cancer research has demonstrated the existence of circulating tumor cells (CTCs) in cancer patient's blood. Once identified, CTC biomarkers will be invaluable tools for clinical diagnosis, prognosis and treatment. In this review, we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample, to derive enough CTCs for accurate and reproducible characterization of the biophysical, biochemical, gene expressional and behavioral properties of the harvested cells. Because of tumor cell heterogeneity, it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis. By analyzing critical steps and technical issues in ex vivo CTC culture, we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells, relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells.
Collapse
Affiliation(s)
- Ruoxiang Wang
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Gina C Y Chu
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Stefan Mrdenovic
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Alagappan A Annamalai
- Uro-Oncology Research, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Andrew E Hendifar
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Nicholas N Nissen
- Uro-Oncology Research, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - James S Tomlinson
- Department of Surgery, West Los Angeles VA Hospital, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
| | - Michael Lewis
- Department of Pathology, West Los Angeles VA Hospital, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
| | | | - Hsian-Rong Tseng
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA
| | - Edwin M Posadas
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Michael R Freeman
- Uro-Oncology Research, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Stephen J Pandol
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Haiyen E Zhau
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Leland W K Chung
- Uro-Oncology Research, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.,Uro-Oncology Research, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
18
|
Wallace AN, Robinson CG, Meyer J, Tran ND, Gangi A, Callstrom MR, Chao ST, Van Tine BA, Morris JM, Bruel BM, Long J, Timmerman RD, Buchowski JM, Jennings JW. The Metastatic Spine Disease Multidisciplinary Working Group Algorithms. Oncologist 2015; 20:1205-15. [PMID: 26354526 DOI: 10.1634/theoncologist.2015-0085] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Accepted: 07/17/2015] [Indexed: 12/25/2022] Open
Abstract
The Metastatic Spine Disease Multidisciplinary Working Group consists of medical and radiation oncologists, surgeons, and interventional radiologists from multiple comprehensive cancer centers who have developed evidence- and expert opinion-based algorithms for managing metastatic spine disease. The purpose of these algorithms is to facilitate interdisciplinary referrals by providing physicians with straightforward recommendations regarding the use of available treatment options, including emerging modalities such as stereotactic body radiation therapy and percutaneous tumor ablation. This consensus document details the evidence supporting the Working Group algorithms and includes illustrative cases to demonstrate how the algorithms may be applied.
Collapse
Affiliation(s)
- Adam N Wallace
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Clifford G Robinson
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jeffrey Meyer
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Nam D Tran
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Afshin Gangi
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Matthew R Callstrom
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Samuel T Chao
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Brian A Van Tine
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jonathan M Morris
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Brian M Bruel
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jeremiah Long
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Robert D Timmerman
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jacob M Buchowski
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| | - Jack W Jennings
- Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Department of Internal Medicine, and Department of Orthopaedic Surgery, Washington University School of Medicine, Saint Louis, Missouri, USA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Neurooncology Program, H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, and Department of Orthopedics, University of South Florida College of Medicine, Tampa, Florida, USA; Department of Interventional Radiology, University of Strasbourg School of Medicine, Strasbourg, France; Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA; Department of Anesthesiology and Pain Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
19
|
Bataille R. The multiple myeloma bone eco-system and its relation to oncogenesis. Morphologie 2015; 99:31-7. [PMID: 26005000 DOI: 10.1016/j.morpho.2015.03.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 03/27/2015] [Indexed: 11/15/2022]
Abstract
Pure lytic bone lesions are the hallmark of myeloma (MM). MM is the only hematological malignancy associated with lytic bone lesions and the mechanisms of bone destruction are well documented both at the cellular and molecular levels. An uncoupling bone process characterizes MM, with stimulation of bone resorption and inhibition of bone formation. The capacity of MM cells to directly or indirectly inhibit bone formation is specific of MM, although many carcinomas have the capacity to stimulate bone resorption, directly or indirectly in a similar way to MM. Few MM do not develop bone lesions, while true sclerotic MM remain exceptional. Inhibition of bone formation is the major event explaining the transition from MGUS to overt MM. It is now well documented that bone cells regulate MM cell growth, osteoclast stimulating MM cell growth and osteoblasts inhibiting it. Progression of MM from MGUS is characterized by the selection of MM clones able to inhibit osteoblasts, favoring tumor growth. These data underline the interest of new treatments able to regenerate bone.
Collapse
Affiliation(s)
- R Bataille
- Institut de cancérologie de l'Ouest, université d'Angers, 2, rue Moll, 49933 Angers cedex 9, France; CRCNA UMR Inserm 892, IRS UN, 44000 Nantes, France.
| |
Collapse
|
20
|
Hsu YL, Tsai EM, Hou MF, Wang TN, Hung JY, Kuo PL. Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2014; 62:11933-11940. [PMID: 25415928 DOI: 10.1021/jf5042905] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
This study is the first to demonstrate that parathyroid hormone-related protein (PTHrP), produced by human breast cancer cells after exposure to phthalate esters, contributes to bone metastasis by increasing osteoclastogenesis. This is also the first to reveal that obtusifolin reverses phthalate esters-mediated bone resorption. Human breast cancer cells were treated with dibutyl phthalate (DBP), harvested in conditioned medium, and cultured to osteoblasts or osteoclasts. Cultures of osteoblasts with DBP-MDA-MB-231-CM increased the osteoclastogenesis activator RANKL (receptor activator of nuclear factor κ-B ligand) and M-CSF (macrophage colony-stimulating factor). PTHrP was secreted in MDA-MB-231 cells. DBP-MDA-MB-231-CM reduced osteoblasts to produce osteoprotegerin, an osteoclastogenesis inhibitor, while DBP mediated PTHrP up-regulation, increasing IL-8 secretion in MDA-MB-231 and contributing to breast cancer-mediated osteoclast differentiation and bone resorption. Obtusifolin, a major bioactive compound present in Cassia tora L., suppressed phthalate esters-mediated bone resorption. Therefore, obtusifolin may be a novel anti-breast-cancer bone metastasis agent.
Collapse
Affiliation(s)
- Ya-Ling Hsu
- Graduate Institute of Medicine, College of Medicine, ‡Institute of Clinical Medicine, College of Medicine, §Department of Public Health, College of Health Science, ∥School of Medicine, College of Medicine, ⊥Research Center for Environmental Medicine, Kaohsiung Medical University , Kaohsiung 807, Taiwan
| | | | | | | | | | | |
Collapse
|
21
|
Rordorf T, Hassan AA, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B. Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. Breast 2014; 23:511-25. [PMID: 24986766 DOI: 10.1016/j.breast.2014.05.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2013] [Revised: 04/16/2014] [Accepted: 05/15/2014] [Indexed: 01/07/2023] Open
Abstract
Bone is the most common site of distant metastases in breast cancer that can cause severe and debilitating skeletal related events (SRE) including hypercalcemia of malignancy, pathologic fracture, spinal cord compression and the need for palliative radiation therapy or surgery to the bone. SRE are associated with substantial pain and morbidity leading to frequent hospitalization, impaired quality of life and poor prognosis. The past 25 years of research on the pathophysiology of bone metastases led to the development of highly effective treatment options to delay or prevent osseous metastases and SRE. Management of bone metastases has become an integral part of cancer treatment requiring expertise of multidisciplinary teams of medical and radiation oncologists, surgeons and radiologists in order to find an optimal treatment for each individual patient. A group of international breast cancer experts attended a Skeletal Care Academy Meeting in November 2012 in Istanbul and discussed current preventive measures and treatment options of SRE, which are summarized in this evidence-based consensus for qualified decision- making in clinical practice.
Collapse
Affiliation(s)
- Tamara Rordorf
- Department of Oncology, University Hospital, Zürich, Switzerland.
| | | | - Hamdy Azim
- Department of Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Eniu Alexandru
- Institute of Oncology "Prof. Dr. Ion Chiricuta" (IOCN), Cluj-Napoca, Romania
| | - Ozlem Er
- Acibadem University, Acibadem Maslak Hospital, Istanbul, Turkey
| | | | - Zeynep Güral
- I.T.F. Radyasyon Onkolojisi Anabilim Dalı, Istanbul, Turkey
| | | | - Velko Minchev
- University Multiprofile Hospital for Active Treatment and Emergency Medicine, Plovdiv, Bulgaria
| | | | | | - Itzok Takac
- Maribor Teaching Hospital, Maribor, Slovenia
| | | | | | | | | | - Serap Yücel
- Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
| | - Jamal Zekri
- Jeddah King Faisal Specialist Hospital & Research Centre, Khaldia, Saudi Arabia
| | - Basak Oyan
- Yeditepe University Hospital, Istanbul, Turkey
| | | | | |
Collapse
|
22
|
Badraoui R, Boubakri M, Bedbabiss M, Ben-Nasr H, Rebai T. Walker 256/B malignant breast cancer cells improve femur angioarchitecture and disrupt hematological parameters in a rat model of tumor osteolysis. Tumour Biol 2013; 35:3663-70. [PMID: 24318993 DOI: 10.1007/s13277-013-1485-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 11/27/2013] [Indexed: 12/28/2022] Open
Abstract
This study was designed to assess femur angioarchitecture and hematological effects of Walker 256/B cells in a rat model of tumor osteolysis. Tumor osteolysis was induced by in situ inoculation of Walker 256/B malignant cells. Six other rats were sham operated and served as control. Twenty days later, rats were euthanized, and femurs were collected than radiographed. Angioarchitecture [mean lumen diameter (MLD), wall thickness (WTh), Vessel number, volume, and separation (VNb, VV, and VSp respectively)] was studied by histomorphometry at 2 different positions (P1: diaphysis, and P2: metaphysis) of the operated femora. Some hematological parameters were also assessed. Walker 256/B induced marked tumor osteolysis, with cortical perforation and trabecular destruction, associated increase in bone vascularization (increases of VNb and VV and decrease of VSp). Angioarchitecture of W256/B rats was disorganized and showed large MLD and lower WTh. These effects were more prominent in P2. When compared to Sham group, significantly decreases at levels of red blood cell (RBC), hemoglobin (Hb), hematocrit (Ht), and white blood cell (WBC) were observed in W256/B rats. These results suggest that Walker 256/B cells induced tumor osteolysis, improve hypervasculature especially near the tumoral foci (P2) associated hematological disruption. Besides, tumor vessels showed abnormal (enlarged and thinner) and disorganized morphology.
Collapse
Affiliation(s)
- Riadh Badraoui
- Laboratory of Histo-Embryology and Cytogenetic, Medicine Faculty, University of Sfax, 3029, Sfax, Tunisia,
| | | | | | | | | |
Collapse
|
23
|
Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G. Cancer-associated bone disease. Osteoporos Int 2013; 24:2929-53. [PMID: 24146095 PMCID: PMC5104551 DOI: 10.1007/s00198-013-2530-3] [Citation(s) in RCA: 87] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Accepted: 09/25/2013] [Indexed: 12/11/2022]
Abstract
Bone is commonly affected in cancer. Cancer-induced bone disease results from the primary disease, or from therapies against the primary condition, causing bone fragility. Bone-modifying agents, such as bisphosphonates and denosumab, are efficacious in preventing and delaying cancer-related bone disease. With evidence-based care pathways, guidelines assist physicians in clinical decision-making. Of the 57 million deaths in 2008 worldwide, almost two thirds were due to non-communicable diseases, led by cardiovascular diseases and cancers. Bone is a commonly affected organ in cancer, and although the incidence of metastatic bone disease is not well defined, it is estimated that around half of patients who die from cancer in the USA each year have bone involvement. Furthermore, cancer-induced bone disease can result from the primary disease itself, either due to circulating bone resorbing substances or metastatic bone disease, such as commonly occurs with breast, lung and prostate cancer, or from therapies administered to treat the primary condition thus causing bone loss and fractures. Treatment-induced osteoporosis may occur in the setting of glucocorticoid therapy or oestrogen deprivation therapy, chemotherapy-induced ovarian failure and androgen deprivation therapy. Tumour skeletal-related events include pathologic fractures, spinal cord compression, surgery and radiotherapy to bone and may or may not include hypercalcaemia of malignancy while skeletal complication refers to pain and other symptoms. Some evidence demonstrates the efficacy of various interventions including bone-modifying agents, such as bisphosphonates and denosumab, in preventing or delaying cancer-related bone disease. The latter includes treatment of patients with metastatic skeletal lesions in general, adjuvant treatment of breast and prostate cancer in particular, and the prevention of cancer-associated bone disease. This has led to the development of guidelines by several societies and working groups to assist physicians in clinical decision making, providing them with evidence-based care pathways to prevent skeletal-related events and bone loss. The goal of this paper is to put forth an IOF position paper addressing bone diseases and cancer and summarizing the position papers of other organizations.
Collapse
Affiliation(s)
- R Rizzoli
- Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Azim H, Azim HA. Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther 2013; 13:195-201. [PMID: 23406560 DOI: 10.1586/era.12.177] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
In breast cancer, RANK ligand (RANKL) appears to play an important role in the process of chemotaxis between circulating tumor cells and the bone microenvironment, which enables RANK-expressing breast cancer cells to migrate into the bone. Mounting clinical evidence has further demonstrated that the anti-RANKL monoclonal antibody; denosumab is the most effective approach in the prevention of skeletal-related events. On the other hand, inhibiting RANKL in preclinical models, not only reduced breast cancer formation but also decreased the development of lung metastases, suggesting RANKL as a novel target for breast cancer chemoprevention. In addition, recent data have pointed to a potential role of RANKL in the biology of breast cancer arising at a young age. Hence, RANKL emerges as a key molecule, not only in the field of breast cancer bone metastasis but also in the biology of breast cancer as a whole.
Collapse
Affiliation(s)
- Hamdy Azim
- Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt
| | | |
Collapse
|
25
|
Zhao H, Cai W, Li S, Da Z, Sun H, Ma L, Lin Y, Zhi D. Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines. Childs Nerv Syst 2013; 29:1097-105. [PMID: 23559392 DOI: 10.1007/s00381-013-2086-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2013] [Accepted: 03/18/2013] [Indexed: 02/02/2023]
Abstract
OBJECTS To determine the mechanism of neuroblastoma (NB) bone invasion/metastasis, it is necessary to investigate the bone invasion/metastasis-related factors in the bone invasion/metastasis process. Some evidence has suggested that various proteins were involved in bone osteolytic response. The invasion/metastasis property and gene expression of NB, however, are still unknown. METHODS Single-cell suspensions of SY5Y and KCNR cells were injected directly into the femur of nude mice. Radiological and histological analyses, immunohistochemistry analyses, and western blot assay were performed to characterize bone metastasis mechanism in these bone metastasis models. RESULTS SY5Y and KCNR NB cells result in osteolytic responses in bone metastasis model. Osteoprotegerin (OPG), receptor activator of NF-kappaB ligand (RANKL), parathyroid hormone-related peptide (PTHrP), endothelin 1 (ET-1), and CXCR4 were examined and compared among in vitro, in vivo, and normal bone, respectively. PTHrP, OPG, RANKL, and ET-1 except CXCR4 in SY5Y and KCNR NB cells xenografts were strikingly upregulated compared with normal bone and NB cells. However, significantly stronger expression of PTHrP and RANKL was presented than ET-1 and OPG; furthermore, the ratios of expression of PTHrP, RANKL to OPG, and ET-1 were also markedly increased in vivo versus in vitro. CONCLUSIONS Our study provided evidence that NB cell may enhance bone invasion through PTHrP, OPG, RANKL, and ET-1, especially PTHrP and RANKL which may display stronger effects. CXCR4 appeared not participating in bone invasion, but in tumor growth, and homing to bone. Targeting PTHrP, OPG, ET-1, and RANKL may provide a new insight and method for patient therapy by inhibiting NB bone metastasis and invasiveness.
Collapse
Affiliation(s)
- Hongyu Zhao
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China.
| | - Weisong Cai
- Department of Oncology, Shengjing Hospital, China Medical University, Shenyang, China
| | - Shuai Li
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China
| | - Zuke Da
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China
| | - Hanxue Sun
- Department of Pathology, Shengjing Hospital, China Medical University, Shenyang, China
| | - Liang Ma
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China
| | - Yaoxin Lin
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China
| | - Debao Zhi
- Department of Neurosurgery, Shengjing Hospital, China Medical University, Shenyang, China
| |
Collapse
|